Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR-mini-CHP trial in untreated patients aged 80 years or older with diffuse large B-cell lymphoma
jRCTs041230146Phase 2Active, not recruiting
- Sponsor
- National Hospital Organization
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisolone in diffuse large B-cell lymphoma (DLBCL), sponsored by National Hospital Organization. Primary endpoint: 2-year progression-free survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
polatuzumab vedotinrituximabcyclophosphamidedoxorubicinprednisolone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs041230146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230146.